Key Points
- Insider selling: Director David Malcom Rodman sold 2,170 shares on Jan. 9 at $33.27 for $72,195.90, and in early January sold roughly 271,270 shares in total (including Jan. 2, 5 and 12 transactions) for about $9.54 million, leaving him with 61,804 shares after the Jan. 9 trade.
- Market and analyst context: MLYS trades near $33, below its 50-day average of $38.74 but above the 200-day average of $30.89, and analysts hold a consensus " Moderate Buy " rating with an average price target of $47.43 and several firms raising targets into the $52–$56 range.
- Company focus: Mineralys Therapeutics is a clinical-stage biopharmaceutical developing lorundrostat, an oral aldosterone synthase inhibitor targeting hypertension and chronic kidney diseases.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 2,170 shares of the company's stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $33.27, for a total transaction of $72,195.90. Following the sale, the insider directly owned 61,804 shares in the company, valued at $2,056,219.08. This trade represents a 3.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
David Malcom Rodman also recently made the following trade(s):
- On Monday, January 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.32, for a total transaction of $205,167.36.
- On Friday, January 2nd, David Malcom Rodman sold 70,037 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $35.87, for a total transaction of $2,512,227.19.
- On Monday, January 5th, David Malcom Rodman sold 192,715 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $35.02, for a total value of $6,748,879.30.
- On Wednesday, October 15th, David Malcom Rodman sold 10,369 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $43.01, for a total value of $445,970.69.
Mineralys Therapeutics Stock Down 0.1%
NASDAQ:MLYS opened at $32.94 on Wednesday. The business's 50-day moving average price is $38.74 and its two-hundred day moving average price is $30.89. Mineralys Therapeutics, Inc. has a twelve month low of $8.24 and a twelve month high of $47.65. The stock has a market cap of $2.61 billion, a P/E ratio of -11.17 and a beta of 0.49.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.14. On average, equities research analysts expect that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
MLYS has been the subject of a number of research analyst reports. Stifel Nicolaus lifted their price objective on shares of Mineralys Therapeutics from $45.00 to $52.00 and gave the stock a "buy" rating in a report on Friday, December 19th. Weiss Ratings restated a "sell (d-)" rating on shares of Mineralys Therapeutics in a research report on Wednesday, October 8th. HC Wainwright upped their price objective on Mineralys Therapeutics from $52.00 to $56.00 and gave the stock a "buy" rating in a report on Wednesday, November 12th. Finally, Wells Fargo & Company increased their price objective on Mineralys Therapeutics from $50.00 to $55.00 and gave the company an "overweight" rating in a research report on Tuesday, November 11th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $47.43.
Read Our Latest Stock Analysis on Mineralys Therapeutics
Institutional Trading of Mineralys Therapeutics
Institutional investors have recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC grew its stake in shares of Mineralys Therapeutics by 198.2% during the third quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company's stock valued at $40,000 after buying an additional 676 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Mineralys Therapeutics by 51.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,518 shares of the company's stock valued at $34,000 after acquiring an additional 850 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in Mineralys Therapeutics by 14,091.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,264 shares of the company's stock valued at $124,000 after acquiring an additional 3,241 shares during the period. Ameritas Investment Partners Inc. grew its position in Mineralys Therapeutics by 42.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,995 shares of the company's stock worth $54,000 after acquiring an additional 1,197 shares during the last quarter. Finally, Victory Capital Management Inc. bought a new position in Mineralys Therapeutics during the 3rd quarter worth approximately $216,000. 84.46% of the stock is currently owned by hedge funds and other institutional investors.
Mineralys Therapeutics Company Profile
(
Get Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
